Loading publications…
The last 5 uploaded publications
Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification
Carla Montironi, Florian Castet, Philipp K. Haber, Roser Pinyol, Miguel Torres‐Martín, Laura Torrens, Agavni Mesropian, Huan Wang, Marc Puigvehí, Miho Maeda, Wei Qiang Leow, Elizabeth Harrod, Patricia Taik, Jigjidsuren Chinburen, Erdenebileg Taivanbaatar, Chinbold Enkhbold, M. Solé Arqués, Michael Donovan, Swan N. Thung, Jaclyn Neely, Vincenzo Mazzaferro, Jeffrey Anderson, Sasan Roayaie, Myron Schwartz, Augusto Villanueva, Scott L. Friedman, Andrew Uzilov, Daniela Sia, Josep M. Llovet (2022). Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut, 72(1), pp. 129-140, DOI: 10.1136/gutjnl-2021-325918.
Article145 days agoImmunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma
Laura Torrens, Carla Montironi, Marc Puigvehí, Agavni Mesropian, Jack Leslie, Philipp K. Haber, Miho Maeda, Ugne Balaseviciute, Catherine E. Willoughby, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, Miguel Torres‐Martín, Judit Peix, Daniel Geh, Erik Ramón-Gil, Behnam Saberi, Scott L. Friedman, Derek A. Mann, Daniela Sia, Josep M. Llovet (2021). Immunomodulatory Effects of Lenvatinib Plus Anti–Programmed Cell Death Protein 1 in Mice and Rationale for Patient Enrichment in Hepatocellular Carcinoma. Hepatology, 74(5), pp. 2652-2669, DOI: 10.1002/hep.32023.
Article145 days agoCabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma
Roger Esteban-Fabró, Catherine E. Willoughby, Marta Piqué‐Gili, Carla Montironi, Jordi Abril‐Fornaguera, Judit Peix, Laura Torrens, Agavni Mesropian, Ugne Balaseviciute, Francesc Miró‐Mur, Vincenzo Mazzaferro, Roser Pinyol, Josep M. Llovet (2022). Cabozantinib Enhances Anti-PD1 Activity and Elicits a Neutrophil-Based Immune Response in Hepatocellular Carcinoma. Clinical Cancer Research, 28(11), pp. 2449-2460, DOI: 10.1158/1078-0432.ccr-21-2517.
Article145 days agoMolecular insights into early malignant transition of hepatocellular carcinoma
Zhengtao Zhang, H. Li, Lingli Chen, Tao Lü, Xinyi Shentu, Yuanhua Liu, Shuyi Ji, Zhixin Qiu, Yining Zou, Hong Wen, Jing Han, Zhengzeng Jiang, Jie Fan, Dianfan Li, Agavni Mesropian, Roser Pinyol, Josep M. Llovet, Hui Dong, Yuan Ji, Lijian Hui (2025). Molecular insights into early malignant transition of hepatocellular carcinoma. bioRxiv (Cold Spring Harbor Laboratory), DOI: 10.1101/2025.04.14.648739.
Preprint145 days agoTHU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma
Agavni Mesropian, Albert Gris‐Oliver, Ugne Balaseviciute, Martí Torres-Marcen, Jordi Abril‐Fornaguera, Marta Piqué‐Gili, David Camell, Judit Peix, Elisa Fernández-Martínez, Júlia Huguet‐Pradell, Ieva Keraite, Roger Esteban-Fabró, Takayuki Kimura, Alka A. Potdar, Marina Bárcena‐Varela, Katherine E. Lindblad, Amaia Lujambio, Ernesto Guccione, Swan N. Thung, Daniela Sia, Roser Pinyol, Josep M. Llovet (2025). THU-077-YI E7386 enhances lenvatinib’s antitumor efficacy and upregulates ATF4 signalling in preclinical models and human hepatocellular carcinoma. Journal of Hepatology, 82, pp. S431-S432, DOI: 10.1016/s0168-8278(25)01237-1.
Article145 days ago